SCHEMBL29566782

SCHEMBL29566782

CC1(C)CCC(c2cc(Oc3ccccc3)nc(NS(=O)(=O)c3ccccc3)n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ PGR P06401 5/20 0.40
▸ GAA P10253 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ MAPT P10636 2/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ FFAR1 O14842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309955 1.00 TSHR (0.46) TSHRSMN1; SMN2PGRGAAPKM
SCHEMBL26811032 0.90 TSHR (0.50) TSHRSMN1; SMN2PGRGAAPKM
SCHEMBL26811008 0.87 TSHR (0.46) TSHRSMN1; SMN2PGRGAAPKM
SCHEMBL26811003 0.87 TSHR (0.48) TSHRSMN1; SMN2PGRGAAPKM
SCHEMBL26811034 0.87 TSHR (0.47) TSHRSMN1; SMN2PGRGAAPKM
SCHEMBL26865625 0.85 TSHR (0.46) TSHRSMN1; SMN2PGRGAAPKM
SCHEMBL26811036 0.85 TSHR (0.46) TSHRSMN1; SMN2PGRGAAPKM
SCHEMBL26811002 0.84 TSHR (0.46) TSHRSMN1; SMN2PGRGAAPKM
SCHEMBL29566504 0.82 TSHR (0.44) TSHRSMN1; SMN2PGRGAAPKM
SCHEMBL24310498 0.82 TSHR (0.44) TSHRSMN1; SMN2PGRGAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback